Search results
Results from the WOW.Com Content Network
Pomalidomide, sold under the brand names Pomalyst and Imnovid, [7] [8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. [ 7 ] Pomalidomide was approved for medical use in the United States in February 2013, [ 10 ] and in the European Union in August 2013. [ 8 ]
Pomalidomide was submitted for FDA approval on April 26, 2012 [27] and on 21 June it was announced that the drug would get standard FDA review. A marketing authorization application was filed to EMA 21 June 2012, where a decision could come as soon as early 2013.
The drug, renamed by that point as pomalidomide, advanced into phase 3 trials. Those trials also went very well and led to Celgene filing for U.S. and European regulatory approval in 2012. Present
Pomalidomide was approved in February 2013 by the FDA as a treatment for relapsed and refractory multiple myeloma. [97] It received a similar approval from the European Commission in August 2013, and is expected to be marketed in Europe under the brand name Imnovid. [98]
Celgene Corporation Announces Pomalidomide Will Be Reviewed at FDA Advisory Committee ODAC will discuss pomalidomide NDA for the treatment of patients with relapsed and refractory multiple myeloma ...
Celgene Corporation Provides Update on FDA Advisory Committee for Pomalidomide SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (Nasdaq: CELG ) today announced it was notified by the U.S. Food ...
Drug Manufacturer Indication Crizotinib: PF Prism: ALK-positive systemic anaplastic large cell lymphoma: Trastuzumab deruxtecan: Daiichi Sankyo: HER2-positive gastric or gastroesophageal junction adenocarcinoma, previously treated with trastuzumab: Umbralisib: TG Therapeutics: marginal zone lymphoma, previously treated with an anti-CD20-based ...
In the following video, Motley Fool health care bureau chief Brenton Flynn discusses an upcoming FDA decision on this Sunday, Feb. 10, on whether to approve Celgene's drug pomalidomide, which is ...